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Abstract: In this study, we extracted prostate cell-specific gene sets (metagenes) to define the epithelial
differentiation status of prostate cancers and, using a deconvolution-based strategy, interrogated
thousands of primary and metastatic tumors in public gene profiling datasets. We identified a
subgroup of primary prostate tumors with low luminal epithelial enrichment (LumElow). LumElow
tumors were associated with higher Gleason score and mutational burden, reduced relapse-free
and overall survival, and were more likely to progress to castration-resistant prostate cancer
(CRPC). Using discriminant function analysis, we generate a predictive 10-gene classifier for clinical
implementation. This mini-classifier predicted with high accuracy the luminal status in both primary
tumors and CRPCs. Immunohistochemistry for COL4A1, a low-luminal marker, sustained the
association of attenuated luminal phenotype with metastatic disease. We found also an association of
LumE score with tumor phenotype in genetically engineered mouse models (GEMMs) of prostate
cancer. Notably, the metagene approach led to the discovery of drugs that could revert the low
luminal status in prostate cell lines and mouse models. This study describes a novel tool to dissect
the intrinsic heterogeneity of prostate tumors and provide predictive information on clinical outcome
and treatment response in experimental and clinical samples.
Keywords: prostate cancer; tumor classification; predictive biomarkers; gene signature; gene classifier
1. Introduction
Prostate cancer is the most common cancer and a leading cause of cancer death in western
countries [1]. Clinical evolution of prostate cancer is highly heterogeneous ranging from indolent
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to very aggressive tumors that rapidly progress to metastatic disease [2]. Whereas localized tumors
are curable, a substantial fraction of patients with metastatic prostate cancer treated with androgen
deprivation therapy (ADT) rapidly progress to lethal castration-resistant prostate cancer (CRPC).
A critical issue is the identification of factors that distinguish indolent from aggressive tumors and,
among primary and metastatic tumors, those that are prone to develop resistance to ADT and will
likely benefit from alternative therapeutic strategies. Therefore, knowledge of the genetic, molecular,
and biological characteristics of the tumors might allow the discovery and implementation of targeted
therapeutic approaches tailored to the individual patients to prevent disease recurrence and avoid
treatment resistance.
Genomic analyses of prostate tumors have provided information about molecular features
associated with disease progression and resistance to current treatments [3,4]. Previous studies have
proposed classifications of prostate tumors based on molecular markers, biological criteria, and gene
expression patterns to identify tumors with different risk of progression, recurrence, and treatment
resistance [5–9]. However, a classification of primary cancers that is strictly based on prostate epithelial
cell features and interrogates the degree of prostate-specific differentiation is lacking.
The prostate gland is composed of a pseudostratified epithelium containing highly differentiated
luminal secretory cells and a minor fraction of basal cells, which are less differentiated and may represent
the normal stem/progenitor cells in the prostate [5,7,10]. Although the issue of cell origin of human
prostate cancer is still controversial, experimental evidence in mouse models indicates that both luminal
and basal cells can act as tumor progenitor cells and give rise to prostate adenocarcinomas [11–13].
Nevertheless, primary prostatic adenocarcinomas, the most frequent type of prostate tumors, have
a predominantly luminal phenotype characterized by androgen receptor (AR) positivity and active
AR signaling [14]. Interestingly, metastatic CRPCs emerging after ADT and next-generation AR
pathway inhibitors (ARPIs) have increasingly non-luminal features, suggesting that subpopulations of
non-luminal, less differentiated cells with basal/stem-like or neuroendocrine features might come into
play during disease progression and emergence of resistance [15]. This phenotypic plasticity could
be ascribed to the expansion of preexisting non-luminal progenitor/stem cells or dedifferentiation of
luminal-type progenitor cells under the selective pressure of the treatment [16].
In this study, we developed a novel approach to probe the representation of different cell
phenotypes and the divergence from the normal epithelial cell differentiation in prostate tumors
starting from gene expression data of bulk tumor tissues. The method is based on epithelial cell-specific
gene signatures (metagenes) and could be used for prognostic indications and therapeutic guidance in
prostate cancer patients.
Analysis of gene expression data from tumors must account for the high cellular heterogeneity of
bulk tissue samples containing a mixture of different cell types. Several reports have described methods
based on deconvolution of transcriptomic data obtained from normal tissue into cell type-specific
profiles [17,18]. By calculating the enrichment scores from these profiles, cell type-specific composition,
such as stromal, immune, or cancer stem cell prevalence, can be inferred in heterogeneous tissues
like solid tumors [18]. Using a conceptually similar approach, we analyzed gene expression data
from about 2000 prostate tumor samples in multiple datasets. To reach our goal, we applied a novel
strategy to dissect within prostate tumors, the differential enrichment of prostate cell-specific metagenes
representative of the luminal and basal epithelial cell phenotype. We hypothesized that prostate
tumors with increasingly aggressive features and less prone to respond to ADT would display a
progressive divergence from the normal epithelial state and an imbalance of the expression of the
epithelial cell-specific metagenes.
We found that primary tumors exhibited highly variable luminal and basal enrichment scores.
Notably, tumors with attenuated luminal metagene enrichment displayed more aggressive traits than
tumors exhibiting high luminal enrichment. Low luminal enrichment was consistently associated with
high Gleason score, increased biochemical recurrence, and reduced overall survival. Furthermore,
CRPCs had prevalently attenuated luminal metagene expression, suggesting that the low luminal
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phenotype might predispose to castration resistance. To facilitate the clinical application of this
concept, we also developed using discriminant function analysis (DFA), an integrated 10-gene classifier
that accurately subdivided both primary and metastatic prostate tumors based on the degree of
luminal enrichment. Interestingly, a single gene in the mini-classifier marking low luminal tumors was
associated with high Gleason score and was highly predictive of metastatic behavior in hormone-naïve
prostate tumors. Application of the metagene scoring system to genetically modified mouse models
(GEMMs) further revealed a consistent association between low luminal enrichment and aggressive
phenotypes, such as invasive and metastatic behavior. The metagene approach applied to GEMMs
and human cell lines provided also insights into drugs that could be used to revert tumors to a higher
luminal status and enhance treatment response or prevent emergence of resistance.
This study describes a novel approach to stratify prostate tumors based on biological features
intrinsic to the prostate epithelium and reflecting the persistence or loss of the differentiated epithelial
cell phenotype. Due to its simplicity and efficiency, after further preclinical validation, this method
may be suitable for clinical application to assess the degree of luminal differentiation in individual
tumors and guide prognostic assessment and therapeutic decisions.
2. Results
2.1. Prostate Cell-Specific Metagenes Dissect Tumor Phenotypic Variability
We applied a prostate-specific metagene approach to assess the prevalence and degree of
differentiation of luminal and basal epithelial cells in tissue samples from primary and metastatic
prostate tumors. The overall experimental approach is outlined in Supplementary Figure S1.
Our working hypothesis was that deviations from the predominant enrichment of luminal-type
cell features in the transcriptomic profile might inform on the biological characteristics of the individual
tumors and allow a sub-classification in tumor subtypes with different prognostic and therapeutic
relevance. To this end, we derived lists of genes or metagenes representative of the main cell components
of the normal prostatic tissue and applied them to bulk transcriptomic data of human prostate cancers.
To generate cell type-specific metagenes, we took advantage of published transcriptomic data of the
main cell types in the human prostate gland: i.e., luminal, basal, stromal fibromuscular, and endothelial
cells [10]. Transcriptomic profiling was performed on the four cell populations isolated by magnetic
cell sorting (MACS) with cell type-specific monoclonal antibodies from benign tissue areas obtained
from radical prostatectomy specimens [10]. The set of monoclonal antibodies applied for MACS
included CD104 or ITGB4 for basal cells, CD26 or DPP4 for luminal secretory cells, CD49a or ITGA1
for stromal fibromuscular cells, and CD31 or PECAM1 for stromal endothelial cells. Gene expression
data were generated using the Affymetrix platform (U133Plus 2.0 GeneChip). Applying differential
gene expression analysis to the transcriptomic data, we extracted lists of genes that were highly
differentially expressed between the four cell types and exhibited high cell type specificity (Figure 1A)
(see Section 4). The gene lists or metagenes represented the transcriptome of the four cell types in the
normal context and contained many molecular features already described for each specific cell type
(Supplementary Table S1). Accordingly, basal keratins (KRT4, KRT5, KRT14, KRT15) were enriched
in the basal metagene (BM). Mesenchymal transcription factors (TWIST1/2, ZEB2) were enriched in
fibromuscular stroma metagene (FSM), while the endothelial stroma metagene (ESM) contained genes
specific of endothelial cells. The luminal metagene (LM) was particularly enriched of genes highly
expressed in the prostate gland (e.g., TRIM36 and members of the solute carrier family) and regulated
by androgens [19].
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Figure 1. Extraction of prostate cell type-specific gene signatures and application to clinical prostate 
tumors. (A) Differential expression analysis was performed using t-test to extract genes selectively 
overexpressed among 4 different cell types of human prostate glands (see Section 4). Heatmap shows 
the unique expression patterns of each indicated cell type-specific metagene (B) Luminal metagene 
enrichment (LumE) scores using single-sample gene set enrichment analysis (GSEA) (ssGSEA) 
approach (see Section 4) in primary prostate cancer from the Taylor, Setlur, and The Cancer Genome 
Atlas (TCGA) datasets. Samples were ordered with increasing score values. (C) Key descriptive 
parameters of the distribution of luminal metagene scores are reported and plotted for the indicated 
datasets. NES, normalized enrichment scores. (D,E) LumE scores in normal (D) and cancer (E) tissue 
samples from TCGA-pancancer dataset. Samples are grouped by organ site and ordered from highest 
to lowest median value. Area under the receiver-operator characteristic (ROC) Curve (AUC) values 
are indicated. AUC values close to or equal to 1.00 (with asterisks) significantly classify prostatic 
versus non-prostatic tissue (normal or cancer tissue). Metagene enrichment scores are shown at the z-
log2 scale. 
Figure 1. Extraction of prostate cell type-specific gene signatures and application to clinical prostate
tumors. (A) Differential expression analysis was p rformed sing t-test to extract genes selectively
overexpressed among 4 different cell types of human prostate gla ds (see Section 4). Heatmap shows
the unique expression patterns of ach indicated cell type-specific metagene (B) Luminal metagene
enrichment (LumE) scores using single-sample g ne s t enrichm nt analysis (GSEA (ssGSEA) approach
(see Sectio 4) in primary prostate cancer from the Taylor, Setlur, and The Cancer Genome tlas (TCG
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Next, we applied a deconvolution strategy based on single-sample gene set enrichment analysis
(ssGSEA) [8,20] using the generated metagenes to interrogate the transcriptome of human primary
prostate tumors in a series of published datasets (Figure 1B and Supplementary Table S2). To overcome
potential bias due to the different profiling platforms of the original studies, we used z-log transformation
and standardization (see Section 4), which allowed direct comparison of the enrichment scores across
the different datasets. Thus, for each sample, we calculated the enrichment score or single-sample
metagene (SSM) score for the four metagenes. Inspecting the SSM scores for the luminal and basal
metagenes across Taylor dataset [3], we observed variable degrees of enrichment of both the luminal
and basal score (Supplementary Table S3). Notably, a discrete number of primary prostate tumors
displayed very low luminal enrichment (LumE) compared to the majority of prostate cancer exhibiting
prevalently high LumE score values (Figure 1B). A similar variance was observed for the enrichment
of the basal metagene with a number of tumors exhibiting unexpectedly high basal enrichment (BasE)
scores (Supplementary Figure S2A). We found similar variability in the LumE and BasE scores when
we applied the metagenes to additional datasets (TCGA HiSeqV2_PANCAN_2014_08_22 release) [21],
with a relevant fraction of tumors exhibiting a sharp decline in luminal metagene score (Figure 1B)
and an increase in basal enrichment (Supplementary Figure S2A). SSM scores for endothelial (EndoE)
and fibromuscular (FibroE) metagene showed a more limited variance across the tumor samples in all
the datasets (Supplementary Figure S2B,C). Notably, comparing the metagene enrichment scores in
multiple datasets, we observed similar distribution, median, and deviation from the median of the
enrichment score values across all the datasets despite the use of different transcriptome profiling
technologies (Supplementary Figures S3 and S4). In particular, the normalized enrichment scores (NES)
for the luminal metagene were highly consistent across the different cohorts (Figure 1C). This supports
the validity of our approach to interrogate prostate metagene enrichment using different technology
platforms and data sources. Moreover, changes in LumE and BasE scores reflect increased divergence
from the predominant luminal phenotype and dedifferentiation in a subset of primary tumors.
The luminal metagene was differentially enriched in normal prostate (n = 52) compared to other
normal tissue samples (n = 613) including 17 different anatomical locations (Figure 1D). Furthermore,
based on the area under the curve (AUC) of the receiver-operator characteristic (ROC), the luminal
metagene displayed high ability to classify prostate versus non-prostate normal tissue samples
(AUC = 0.98), indicating that the luminal metagene was very selective for the prostatic tissue despite
an expected similarity with other epithelial tissues such as breast and bladder. Moreover, the
luminal metagene score was significantly higher in prostate cancers and distinguished with very
high accuracy (AUC = 1.00) prostate cancer from non-prostate cancer tumor samples (Figure 1E).
The basal metagene was enriched also in normal prostate. However, other normal epithelial tissue
(i.e., bladder, breast) had similar high values (Supplementary Figure S5). Furthermore, the basal
metagene, despite a good performance in discriminating prostate versus non-prostatic normal tissue
samples (AUC = 0.80), was unable to identify selectively prostate cancers among other tumor tissue
samples (AUC = 0.52) displaying similar score distributions across many tumor types (Supplementary
Figure S5). The fibromuscular metagene score was not significantly different between prostatic and
non-prostatic tissues among both normal and tumor samples, whereas the endothelial metagene
displayed the lowest scores in normal and cancer prostate samples (Supplementary Figure S5).
Collectively, these data indicated that the luminal metagene reflected core components of the
transcriptome of normal prostate epithelial cells and accurately identified both normal and malignant
prostatic tissues among other tissue types, making it a reliable metagene to monitor the epithelial
cell differentiation state in normal and tumor prostatic tissue samples. Interestingly, the evaluation
of the basal, fibromuscular, and endothelial metagenes in the subgroup of tumors with low LumE
compared to non-low LumE tumors revealed that those with low luminal enrichment displayed
unusual high BasE, EndoE, and FibroE scores (Supplementary Figure S6A), suggesting that loss of
luminal characteristics was associated with epithelial dedifferentiation and changes in cellularity.
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2.2. Low Luminal Tumors Exhibit Poor Clinical Outcome and Increased Mutational Burden
The luminal metagene appeared as a reliable tool to monitor the epithelial differentiation state in
prostate tumors. To determine whether the luminal metagene was associated with clinical outcome,
we performed Cox regression analysis overall survival and biochemical recurrence (Figure 2A).
Univariate and multivariate Cox regression analysis showed a significant association of the LumE
score with adverse prognosis for both overall and recurrence-free survival. Conversely, no associations
were seen with the BasE, FibromE, and EndoE scores. Kaplan–Meyer analysis for recurrence-free
survival and overall survival demonstrated that patients with low LumE tumors displayed poorer
outcome than those with high and intermediate LumE score (Figure 2B). We used also an immune
signature generated in an independent study to detect and quantify the level of immune infiltrates
from transcriptomic data in complex tissue samples [18]. The immune signature score did not show
any significant association with survival in the Taylor and Setlur cohorts of primary prostate tumors
(Supplementary Figure S6B). Interestingly, low luminal tumors exhibited on average higher immune
signature enrichment scores than non-LumE low tumors, as also seen with the other metagenes
(Supplementary Figure S6C). Furthermore, LumE scores were significantly lower in lethal prostate
cancers than indolent tumors (Figure 2C). Primary prostate cancer with higher (≥8) Gleason score
had also significantly lower LumE (Figure 2D). Thus, low LumE score was predictive of clinically
aggressive disease, whereas none of the other metagenes per se had an impact on clinical outcome.
Notably, using genomic data available for tumors in the The Cancer Genome Atlas (TCGA) dataset
we found a higher frequency of genetic alterations in low LumE (q1q2) tumors. Specifically, tumors
with low luminal enrichment displayed significantly higher frequencies of ERG gene fusion, PTEN
homozygous deletion, TP53 homozygous deletion and mutation, and MYC amplification (Figure 2E).
In contrast, SPOP mutations, which are generally associated with better prognosis [22], were more
frequent in tumors with high LumE (q3q4). The overall mutational burden was also significantly
higher in low LumE (q1q2) tumors compared to high LumE (q3q4) tumors (Figure 2F). The higher
frequency of mutations corroborates our hypothesis that the level of luminal enrichment may reflect the
phenotypic plasticity associated with disease progression, independently of the nature of the specific
mutations identified in advanced tumors.
2.3. Association of Prostate-Specific Features in LumE-Defined Tumor Subtypes
We applied GSEA to identify molecular pathways differentially enriched in tumors with high
and low LumE score in the TCGA and Taylor datasets. Primary tumors with high LumE profile were
enriched in genes canonically upregulated in prostate cancer (Figure 3A,B; Supplementary Tables S4
and S5). Conversely, low LumE tumors were enriched of genes downregulated in prostate cancer
(Figure 3A). We observed also a relationship between LumE score with genes either up or downregulated
in luminal or basal breast cancers (BC) (Figure 3A). Thus, the luminal metagene enrichment reflected
the degree of differentiation or loss of prostate epithelial markers. Interestingly, also tumors with a high
BasE profile exhibited features canonically downregulated in prostate cancers, whereas the opposite
occurred in low BasE tumors (Supplementary Figure S7). Notably, functional annotation analysis
revealed enrichment of metabolic and secretory pathways in tumors with high LumE score, whereas
molecular pathways related to proliferation, mitogenesis, and chromatin dynamics were positively
associated with low LumE tumors (Figure 3C).
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scores in indolent and lethal prostate tumors in the Setlur dataset. P-value calculated with t-test. (D) 
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display significantly lower LumE scores in both cohorts. P-values calculated with t-test. (E) TCGA 
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genome altered than higher LumE scores (q3q4). Metagene enrichment scores are shown at the z-log2 
scale. 
  
Figure 2. Luminal metagene is associated with aggressive features and poor prognosis. (A) Univariate
and multivariate Cox regression analysis in the TCGA and Setlur datasets (recurrence-free survival
and overall survival, respectively) using LumE, BasE, FibromE, and EndoE metagene scores. LumE is
significantly associated with poor prognosis in both cohorts. Association with other metagenes was
not significant. (B) Kaplan–Meyer analysis of recurrence-free survival (TCGA) and overall survival
(Setlur) based on LumE score. Patients were allocated in 3 groups depending on score values: LumElow
(quartile q1), LumEintermed (quartiles q2 and q3), and LumEhigh (quartil q4). (C) Comparison of LumE
scores in indolent and lethal prostate tumors in the Setlur dataset. P-value calculated with t-test.
(D) Correlation between LumE and Gleason scores in Setlur and TCGA datasets. High Gleason samples
display significantly lower LumE scores in both cohorts. P-values calculated with t-test. (E) TCGA
samples with lower LumE scores (quartiles q1 and q2) display more genetic alterations than those
having higher scores (quartiles q2 and q4). Significant differences were calculated with Fisher’s exact
test (threshold p-value < 0.01). Significance: −log10 (p-value). Blue bars: more alterations in LumE q1q2.
Red bar: more alterations in LumE q3q4. (F) Association between luminal score and fraction of genome
altered in TCGA dataset. Samples with lower LumE scores (q1q2) display higher fraction of genome
altered than higher LumE scores (q3q4). Metagene enrichment scores are shown at the z-log2 scale.
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Figure 3. Luminal metagene score is associated with androgen receptor signaling and is attenuated in
castration-resistant prostate tumors. (A) Gene set enrichment analysis (GSEA) in tumors with higher
or lower LumE scores in The Cancer Genome Atlas (TCGA) and Taylor datasets. NES, normalized
enriched scores. (B) GSEA plots with prostate-specific genesets showing enrichment in tumors with
high LumE scores. (C) GSEA with KEGG pathways showing enrichment in tumors in TCGA dataset
with either higher or lower LumE scores. (D) GSEA plots with androgen upregulated genes showing
enrichment in high LumE tumors in Taylor (left) and TCGA (right) datasets. (E) Luminal scores in
primary tumors versus castration-resistant prostate cancers (CRPCs) in the Grasso dataset. Luminal
scores are significantly lower in CRPCs. (F) Unsupervised hierarchical clustering analysis of primary
tumors and CRPCs based on the luminal metagene. Note the robust clusterization of CRPCs based on
the attenuated luminal signature. (G) Distribution of metagene scores in primary tumors and CRPCs.
Samples are ordered by increasing LumE scores. Note the prevalently lower LumE scores in CRPCs
compared to primary tumors. For GSEA threshold of significance is FDR < 0.01.
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Responsiveness to androgen stimulation is an important aspect of normal luminal epithelial cells.
Thus, the degree of luminal enrichment could be a surrogate marker of AR signaling proficiency and
sensitivity to AR-targeting therapy. Interestingly, application of the metagene scoring system to gene
expression data from LNCaP cells showed a significant time-dependent increase of the LumE score
and a concomitant decrease of the BasE score upon androgen stimulation (Supplementary Figure S8A).
Furthermore, androgen-activated genes were significantly enriched in tumors with high LumE score
(Figure 3D), whereas genes downregulated by androgens were enriched in tumors with high BasE score
(Supplementary Figure S8B). To examine further the relation between luminal metagene enrichment
and susceptibility to AR signaling inhibition, we compared hormone-naïve primary tumors and CRPCs
in distinct datasets [23,24]. Notably, both primary CRPCs and metastatic CRPCs had significantly
lower LumE scores compared to hormone-naïve primary tumors, suggesting that decreased luminal
differentiation may favor castration-resistance (Supplementary Figure S8C,D).
To further support the link between luminal metagene and castration resistance, we evaluated the
metagene scores in primary tumors and CRPCs in a large dataset [25]. Consistent with our hypothesis,
LumE scores were significantly lower among CRPCs than primary tumors (Figure 3E). Among the other
metagenes, BasE and EndoE scores were not significantly different, whereas the average fibromuscular
metagene score was significantly lower in CRPCs (Supplementary Figure S9). Strikingly, unsupervised
hierarchical clustering showed that the luminal metagene separated primary tumors from CRPCs
(Figure 3F) and, in supervised analyses, low LumE scores were preferentially associate with CRPCs
(Figure 3G). With the exception of the FibroE, the other metagenes performed poorly in supervised
analyses, being unable to discriminate between the two groups (Supplementary Figure S10).
Increasing numbers of CRPCs, particularly after treatment with next-generation ARPIs, exhibit
a neuroendocrine phenotype, a phenomenon that has been linked to phenotypic plasticity and
dedifferentiation driving treatment resistance [16,26]. Applying the metagene approach we found
independent clustering of neuroendocrine CRPCs (NE-CRPCs) compared to adeno-CRPCs (Figure 4A).
Indeed, most NE-CRPCs formed in an intermediate heterogeneous group with adeno-CRPCs forming
two distinct clusters with relatively higher and lower luminal enrichment, respectively. Indeed,
sub-clusters of both NE and Adeno-CRPCs can be seen examining the clustering tree, which might
reflect the evolution and transition of castration-resistant tumors through intermediate stages of
dedifferentiation and loss of luminal phenotype during disease progression. Whether these sub-clusters
of NE and Adeno-CRPCs with different retention of luminal features are associated with distinctive
clinical features remains to be investigated.
Our data indicate that loss of epithelial cell differentiation is more evident in metastatic tumors.
However, whether the luminal phenotype is retained at the metastatic sites is unknown. Using
transcriptomic data from metastases of prostate cancer at distinct organ sites [27], we assessed the
degree of retention or loss of luminal differentiation. We focused on the luminal metagene because
of its association with clinical outcome in patients with primary tumors. Intriguingly, the level of
luminal enrichment varied considerably among the distinct metastatic sites as seen by supervised
clustering analysis (Figure 4B). Bone metastases had higher LumE scores, whereas lymph node and
visceral (e.g., liver, lung) metastases exhibited mainly lower LumE scores (Figure 4C). The differences
in LumE scores between bone and the other metastatic sites (i.e., lymph node, liver, and lung) were
highly statistically significant. The other metagene scores also varied among metastatic sites, although
the overall variance was reduced and only in few cases the difference between bone and visceral
metastases was significant (Supplementary Figure S11). Thus, metastatic prostate cancer cells to the
bone retain luminal features and likely AR signaling proficiency, which may make them relatively
more responsive to AR modulators compared to visceral metastases. These data are consistent with the
notion that AR is still expressed and active in these metastatic tumors as shown by Kumar et al. [27].
However, our study highlights for the first time a relative enrichment of luminal genes in bone versus
visceral metastasis. This finding deserves further investigation. Collectively, these data indicate that
the luminal metagene can identify, among both primary and metastatic tumors, those tumors that
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deviate from the canonical prostate-specific luminal-type profile and are more likely to progress to
castration-resistance, metastatic, and lethal cancers.
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Figure 4. Enrichment scores in aggressive prostate tumors and metastases. (A) Unsupervised
hierarchical clustering analysis of adenocarcinoma (Adeno) and neuroendocrine (NE)
castration-resistant prostate cancers (CRPCs) based on luminal metagene expression. Note the
presence of sub-clusters of both Adeno and NE CRPCs with different degrees of luminal enrichment.
(B) Metagene score distribution in tissue samples from different metastatic sites. (C) Luminal enrichment
scores in metastatic prostate tumors at distinct organ sites. p-values relative to the comparison of
luminal enrichment scores between bone versus lung, liver, and lymph node metastases are indicated.
2.4. Extraction of a Mini-Classifier Gene Set and Orthogonal Validation by Immunohistochemistry
To facilitate the clinical application of the metagene approach, we used discriminant function
analysis (DFA) to obtai a cl ssifi ti mod l predicting whether a tumor belongs to the LumElow
or to the non-LumElow group, but based on th expression of a small set of genes (s e Section 4).
DFA ide tifies the optimal combination and number f variable that best discriminate between
predefined sam le populatio s (e.g., low and high LumE tumors). The TCGA cohort was used
to rive the DFA-based clas ification model, which was further validated in the Setlur, Tayl r,
and Glinsky datasets. Samples in each dataset were labeled bas d on the LumE score: “LumElow“group
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(quartile q1 with lowest values) and the “non-LumElow” group (quartiles q2, q3, and q4). We filtered
out any gene that was not present in all the profiling platforms. Then, feature (gene) selection was
performed on common genes between all 4 datasets (n = 5812) with fold change >1.25 or <−1.25
between the 2 groups of samples (n = 3432). The 10 genes with highest discriminant performance
were selected and the discriminant coefficients calculated (Supplementary Figure S12). Notably, the 10
genes included in the mini-classifier were not part of the initial metagenes and were overexpressed in
either LumElow tumors (i.e., C3, COL4A1, CYP7A1, MORF4l2, RRM1) or non-LumElow tumors (i.e.,
AMACR, ANXA3, IDH1, KLK3, SLC13A3). Up to 93% of samples within the TCGA were correctly
classified into the corresponding groups. The 10-gene classifier model was tested in the Setlur, Taylor,
and Glinsky datasets, and the percentage of correctly classified samples computed (Figure 5A). To test
the performance on the Ehro dataset, lacking the gene MORF4L2, a model based on the 9 remaining
genes was re-trained in TCGA samples and validated in Erho dataset (Figure 5A). Overall, the classifier
gave rise to high percentages of correct sample classifications in the testing datasets, between 78% and
85%. As expected, predicted LumElow tumors displayed significantly higher BasE, EndoE, and FibromE
scores (Supplementary Figure S13), and poor clinical outcome in recurrence-free (TCGA) and overall
(Setlur) survival analyses (Figure 5B).
The mini-classifier exhibited ability similar to the luminal metagene in identifying variation
in epithelial differentiation in prostate tumors. Consistent with the luminal metagene approach,
the 10-gene classifier divided into unsupervised clustering analysis primary tumors and CRPCs based
on the attenuation of luminal features in CRPCs (Figure 5C). Adeno-CRPCs and NE-CRPCs were also
divided by unsupervised clustering into distinct subgroups based on the mini-classifier predictions
(Figure 5D). Thus, the 10-gene classifier is an accurate surrogate of the luminal metagene for identifying
phenotypic changes in tumor samples at different stages of the disease.
To support our findings, we sought to provide an independent validation by assessing protein
expression of classifier genes by immunohistochemistry (IHC) on primary prostate cancers. The purpose
was to determine whether variations of epithelial cell differentiation with attenuated luminal phenotype
could be detected by performing IHC and verify the association with clinical and pathological
parameters. Among the 10 genes in the classifier, COL4A1 was significantly higher in low LumE
tumors and, because of the availability of good antibodies for IHC, was selected for further orthogonal
validation in an independent set of hormone-naïve primary prostate tumors (n = 46) with clinical and
follow-up data (Figure 6A). COL4A1 immuno-staining in the tissue microarray was scored by three
independent pathologists. The analysis revealed a considerable variance in the IHC score within the
patient cohort, with approximately 10% of tumors with very high COL4A1 IHC score indicative of low
luminal phenotype (Figure 6B). Notably, tumors with high level of COL4A1 were highly significantly
associated with greater (≥8) Gleason score (Figure 6C). Moreover, a high COL4A1 IHC score in patients
with primary tumors was significantly associated with metastasis within five years from diagnosis
(Figure 6D). These data were consistent with the association between attenuated luminal phenotype and
adverse clinical behavior. Thus, COL4A1 immunostaining provided an independent complementary
validation of the classifier approach for predicting clinical behavior in patients.
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Figure 5. Extraction and validation of a 10-gene mini-classifier of prostate epithelial differentiation.
(A) Percentage of correctly classified samples using the 10-gene classifier in prostate cancer datasets.
The Cancer Genome Atlas (TCGA) cohort (training set) was used to obtain the predictor model using
discriminant function analysis (DFA) and thereafter tested in Erho, Glinsky, Setlur, and Taylor (testing
sets). (B) Kaplan–Meyer analysis of recurrence-free survival (TCGA) and overall survival (Setlur) based
on the groups predicted by the 10-gene classifier. (C) Unsupervised hierarchical clustering of primary
tumors and metastatic castration-resistant prostate cancers (CRPCs) based on the 10-gene classifier.
Discriminant function analysis (DFA) predicted classes of low (red) and non-low (black) LumE tumors
are indicated at the top. (D) Unsupervised hierarchical clustering of adenocarcinoma (adeno-CRPC)
and neuroendocrine (NE-CRPC) CRPCs based on the 10-gene classifier. DFA predicted classes of low
(red) and non-low (black) LumE tumors.
Cancers 2020, 12, 176 13 of 23
Cancers 2020, 12, x FOR PEER REVIEW 13 of 23 
 
adenocarcinoma (adeno-CRPC) and neuroendocrine (NE-CRPC) CRPCs based on the 10-gene 
classifier. DFA predicted classes of low (red) and non-low (black) LumE tumors. 
The mini-classifier exhibited ability similar to the luminal metagene in identifying variation in 
epithelial differentiation in prostate tumors. Consistent with the luminal metagene approach, the 10-
gene classifier divided into unsupervised clustering analysis primary tumors and CRPCs based on 
the attenuation of luminal features in CRPCs (Figure 5C). Adeno-CRPCs and NE-CRPCs were also 
divided by unsupervised clustering into distinct subgroups based on the mini-classifier predictions 
(Figure 5D). Thus, the 10-gene classifier is an accurate surrogate of the luminal metagene for 
identifying phenotypic changes in tumor samples at different stages of the disease. 
To support our findings, we sought to provide an independent validation by assessing protein 
expression of classifier genes by immunohistochemistry (IHC) on primary prostate cancers. The 
purpose was to determine whether variations of epithelial cell differentiation with attenuated 
luminal phenotype could be detected by performing IHC and verify the association with clinical and 
pathological parameters. Among the 10 genes in the classifier, COL4A1 was significantly higher in 
low LumE tumors and, because of the availability of good antibodies for IHC, was selected for further 
orthogonal validation in an independent set of hormone-naïve primary prostate tumors (n = 46) with 
clinical and follow-up data (Figure 6A). COL4A1 immuno-staining in the tissue microarray was 
scored by three independent pathologists. The analysis revealed a considerable variance in the IHC 
score within the patient cohort, with approximately 10% of tumors with very high COL4A1 IHC score 
indicative of low luminal phenotype (Figure 6B). Notably, tumors with high level of COL4A1 were 
highly significantly associated with greater (≥8) Gleason score (Figure 6C). Moreover, a high COL4A1 
IHC score in patients with primary tumors was significantly associated with metastasis within five 
years from diagnosis (Figure 6D). These data were consistent with the association between attenuated 
luminal phenotype and adverse clinical behavior. Thus, COL4A1 immunostaining provided an 
independent complementary validation of the classifier approach for predicting clinical behavior in 
patients. 
 
Figure 6. Orthogonal validation of low luminal marker COL4A1 in hormone-naïve primary prostate 
tumors. (A) COL4A1 protein was assessed by immunohistochemistry on a tissue microarray (TMA) 
containing primary prostate tumor samples. Representative images of high (left) and low (right) 
COL4A1 intensity staining. Magnification, 4× (left and upper images) and 20× (right image). (B) 
Distribution of COL4A1 immunohistochemistry (IHC) scores in primary tumors (n = 46). (C,D) 
Figure 6. Orthogonal validation of low luminal marker COL4A1 in hormone-naïve primary prostate
tumors. (A) COL4A1 protein was assessed by immunohistochemistry on a tissue microarray (TMA)
containing primary prostate tumor samples. Representative images of high (left) and low (right) COL4A1
intensity staining. Magnification, 4× (left and upper images) and 20× (right image). (B) Distribution of
COL4A1 immunohistochemistry (IHC) scores in primary tumors (n = 46). (C,D) Significant association
of COL4A1 IHC staining with Gleason score (C) and metastasis (D) in primary prostate tumors.
2.5. Application of Luminal Metagene to Mouse Experimental Models
Multiple GEMMs of prostate cancer are currently available and represent a valid resource for
studying the disease [28]. To determine whether GEMMs reproduced a similar variance of the luminal
phenotype as seen in human tumors, we applied our metagenes to published transcriptomic data
from wild type mice and GEMMs [29]. These mouse models recapitulated different pathological
stages from prostate intraepithelial neoplasia (PIN) to adenocarcinoma, CRPC, and metastatic prostate
cancer (Figure 7A and Supplementary Figure S14). Interestingly, we found that more aggressive
GEMMs, such as the NPB, NPK, and APT-P mice with compounded genetic alterations of oncogenes
(e.g., K-Ras, B-Raf ) and tumor suppressor genes (e.g., Pten, Nkx3.1), displayed significantly lower
LumE values compared to less aggressive mouse models and normal (WT) prostate (Figure 7B).
Variance also was observed in BasE scores, with NPB and NPK mice exhibiting the highest mean scores
(Figure 7C). Interestingly, NPB and NPK mice with the lowest LumE score and the highest BasE score
are highly metastatic, sustaining the link between low LumE and aggressive behavior. Consistently
with the data in human samples, mouse tumors with lower LumE score displayed higher BasE, EndoE,
and FibromE scores, resembling the human LumElow tumors (Supplementary Figure S15). Thus, these
data supported the notion that the luminal metagene applies also to mouse models and a low LumE
score identifies invasive and metastatic models similar to human tumors.
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Figure 7. Application of metagene enrichment to genetically engineered mouse models (GEMMs)
of prostate cancer. (A) Genotype and phenotypes of mouse models included in the study. WT,
normal prostate; LGPIN and HGPIN, low-grade and high-grade prostate intraepithelial neoplasia; PC,
prostate cancer; CRPC, castration-resistant prostate cancer; mCRPC, metastatic CRPC. For details see
Supplementary Figure S14B,C LumE (B) and BasE (C) score distribution in mouse models.
2.6. Luminal Metagene and Therapeutic Response in Human and Mouse Experi ental Models
Assessing the luminal metagene score may permit monitoring the phenotypic changes induced by
treatments and eventually inform on the type of biological and therapeutic response. The implemented
therapy could influence the cell differentiation state and be reflected in changes in the luminal metagene
enrichment. Furthermore, a shift toward higher or lower luminal enrichment might predict increased
or decreased susceptibility to AR-targeted therapies. To verify this possibility, we used published
transcriptomic data from GEMMs treated with anticancer drugs [29]. Our hypothesis was that
treatment could influence the degree of luminal differentiation of the tumors, which might predict
a therapeutically beneficial effect. Using pre- and posttreatment RNA-seq data, we computed the
changes in LumE score after treatment in NPB, NPK, APT-P, and TRAMP mice. This bioinformatics
analysis revealed various drugs that affected positively the luminal enrichment score shifting tumor
cells to a more differentiated state (Figure 8A). We focused on compounds that gave the most frequent
and consistent changes across these experimental models, aware of the bias and noise intrinsic in this
type of analysis. Interestingly, in all three models (NPB, NPK, and APT-P) with the lowest starting
LumE score, WP1066 (JAK/STAT inhibitor) and docetaxel (anti-tubulin drug) increased significantly
the LumE score. Dasanitib (Src/Bcr-Abl inhibitor) and LY294002 (PI3 kinase inhibitor) produced a shift
to higher LumE scores in three of the four models (Figure 8A).
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Figure 8. Identification of compounds enhancing luminal metagene enrichment. (A) Compounds
increasing luminal metagene scores (≥2-fold change) in the indicated mouse models. (B) Top ranking
compounds modifying luminal and basal enrichment scores consistently in VCaP and PC3 cells.
(C) Targets and mechanism of action (MOA) of drugs enhancing luminal scores in both VCaP and PC3
cells. Library of Integrated Network-Based Cellular Signatures (LINCS) signature enrichment scores
were defined by CLUE algorithm.
To provide additional support to these findings, we consulted publicly available transcriptomic
data for two prostate cancer cell lines (PC3 and VCaP), which had been profiled before and after
treatment with many drugs/compounds in the context of the Library of Integrated Network-Based
Cellular Signatures (LINCS) project (http://www.lincsproject.org/). Using the transcriptomic data for
the entire library of compounds in the LINCS project, we calculated the corresponding LumE score
in PC3 and VCaP cells for each compound in the database. Interestingly, compounds that scored
positive in GEMMs modulated the luminal phenotype also in the cell lines (Supplementary Figure
S16), although the direction of the changes was not always consistent in the two cell models (e.g.,
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dasanitib and LY294002). This likely reflected differences in cell-specific factors, which will require
further investigation. Indeed, PC3 cells, which are AR-independent and have relatively lower LumE
score, correspond more to the aggressive mouse models examined here.
Interestingly, applying the metagene approach we identified additional compounds that
consistently increased LumE or decreased BasE scores in PC3 and VCaP cells (Supplementary Table S6).
Figure 8B shows the top 10 compounds that induced changes in LumE and BasE scores consistently
in both cell lines. Notably, the list included compounds with very diverse targets, from TOP2A/B,
AMPK, BCL2, FGFR-, and EGFR-associated kinases to serotonin and adrenergic receptors (Figure 8C).
Although the mechanistic link between the molecular targets and the predicted effect on epithelial
cell differentiation is unclear, the possibility of using these drugs to promote a more differentiated
phenotype and perhaps increase the efficacy of AR-directed therapy is intriguing and certainly worth
verifying experimentally.
3. Discussion
The genetic and molecular heterogeneity of prostate cancer is emerging as an important factor
influencing clinical evolution, prognosis, and treatment efficacy. In this study, we provide novel
insights into the phenotypic heterogeneity of primary and metastatic prostate tumors. We show
that probing the divergence of epithelial cell features can inform on the properties of the individual
tumors and reflect the clinical behavior of the disease. To achieve this objective, we constructed
metagenes that dissected the bulk transcriptomic data on the basis of intrinsic prostate cell-specific
features. Specifically, we found that the degree of luminal epithelial enrichment reflected the level of
dedifferentiation, metastatic potential, androgen-dependency, and sensitivity to AR-directed therapies.
Deviation toward an attenuated luminal phenotype depicted tumors prone to clinical adverse behavior
and ineffective response to ADT.
Recent studies have shown that both luminal and basal-type progenitor/stem cells can generate
prostate adenocarcinomas, which in most cases exhibit a predominant luminal phenotype with AR
positivity and dependency on androgen stimulation [30]. We hypothesized that the degree of retention
or divergence from the normal epithelial progenitor/stem cells may alter the context and confer
distinctive properties to the individual tumors. Accordingly, our strategy was to define gene signatures
or metagenes that could assess the relative representation of the diverse cell types in the prostate
gland and estimate the divergence of the tumor cells from the normal state. We found that the
luminal metagene was the most effective at identifying normal prostate from other normal tissues and
at discriminating prostate cancers from other tumor types. Thus, the luminal metagene contained
prostate cell-specific features, identified prostate tissue samples, and gave information on the state
of differentiation of prostate epithelium in both the normal and pathological conditions. Despite the
fact that basal cell signatures have been proposed as tumor classifiers [6], we found that the basal
metagene derived from normal basal epithelial cells was less informative in this context. The basal
cell signature was less able to discriminate prostate tissues from other tissues both in normal and
pathological conditions. Thus, basal epithelial cells are less tissue-specific and may comprise a pool of
progenitor/stem cells with shared characteristics in other epithelial tissues.
According to a precision medicine approach, specific tumor features should guide management
and treatment of patients. Therefore, there is great interest in tools that might predict clinical evolution
and response to treatment in individual cases. Various types of gene classifiers have been proposed to
formulate predictions on clinical outcome in prostate cancer patients [6,7,31]. In a recent study, a gene
classifier developed for breast cancer, PAM50, was applied to primary prostate cancers [5]. In analogy
with breast cancers, primary prostate tumors were divided into three subgroups: luminal A, luminal B,
and basal. Unlike the breast cancer subtypes, luminal B prostate cancers had the poorest prognosis and
were concomitantly predicted to respond better to hormonal therapy, suggesting intrinsic differences
between the predicted subtypes of breast and prostate cancer.
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While the presence of luminal and basal features appears a unifying biological concept that could
be applied to all epithelial tumors, our goal was to provide a more prostate-specific classifier that
would take into account the subtle divergences between normal and pathological states. Indeed,
we successfully constructed a gene signature that estimated quantitatively the degree of luminal
enrichment in individual prostate tumors and resulted in homogeneous and reproducible subgrouping
of prostate tumors across multiple patient cohorts. In this context, tumors with low luminal enrichment
scores displayed increased recurrence rates and concomitantly attenuated AR signaling. Low luminal
enrichment was associated with progression to castration-resistance. Intriguingly, however, CRPCs
comprised a small fraction of tumors that retained a relatively high LumE score, suggesting residual
responsiveness to AR signaling in these individual cases. Furthermore, our metagene approach
detected differences in the degree of luminal enrichment in metastases at different organ sites, which
might also predict loss or retention of susceptibility to AR-directed therapies. Consistently, bone
metastases exhibited a higher luminal score than metastases to lymph node, lung, and liver.
An important aspect is the possibility to predict the potential benefits of therapeutic interventions
in terms of biological response beyond and independently of measurable clinical responses. This would
be particularly useful in borderline cases where it is important to balance the benefits and risks of
treatment intensification. We hypothesized that the assessment of the degree of luminal differentiation
based on the metagene score could serve such purpose by evaluating the evolutionary stage of the tumor
and predicting the biological impact of a specific treatment. Concerning the response to AR-directed
therapies, our data suggest that primary and metastatic prostate cancers with low LumE score might be
less likely to respond to the treatment and would rather benefit from alternative strategies. Collectively,
these results support the possibility of using the metagene approach to assess phenotypic changes as a
biological readout of treatment efficacy in experimental models. This method can also give insights for
designing new therapeutic strategies and testing new drug combinations in model systems prior to
clinical implementation. Furthermore, a similar approach could be applied to characterize biologically
the response to treatments in patients.
Intriguingly, application of our metagene approach to GEMMs and human cell lines provided also
insights into novel strategies that could revert prostate tumors to a more luminal state and perhaps
enhance or restore sensitivity to AR-based therapies. Many of the top-ranking compounds that favored
a luminal phenotype in both GEMMs and cell lines are drugs already in clinical use or in clinical trials
in cancer patients. Notably, a series of compounds with non-canonical mechanisms of anticancer
activity and molecular targets (e.g., adrenergic receptor antagonists) but with preclinical evidence of
efficacy in prostate cancer [32–34] emerged from our analysis. The finding of neurotransmitter receptor
antagonists as potential modulators of luminal epithelial differentiation is particularly intriguing in
light of the emerging role of innervation and neurotransmitter signaling in promoting tumor growth
and establishing a pro-tumorigenic microenvironment [35–37]. Future studies will have to validate
these hypotheses in preclinical models and assess the efficacy of these novel treatment modalities in
clinical trials. If confirmed in preclinical models, these concepts could be readily tested in patients.
4. Methods
4.1. Metagene Discovery
Oudes datamatrix, containing high-quality hybridizations from four prostate cell types, was used
to extract differentially expressed genes [10]. Gene expression profiles were generated using Human
Genome U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA). Five separate biological replicates
of each sorted cell population were assayed to produce a data set of 20 chips. The GeneChips were
prepared, hybridized, and scanned according to the protocols provided by Affymetrix as previously
described [10]. Briefly, raw CEL files were retrieved and signal intensity obtained upon RMA processing
using RMAExpress software. RLE/NUSE plots were calculated to check for quality control raw files.
Differential expression analysis was performed using t-test to extract genes overexpressed in each
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cell compartment versus the others (i.e., (i) CD104/ITGB4 versus non-CD104/ITGB4; (ii) CD26/DPP4
versus non CD26/DPP4; (iii) CD49a/ITGA1 versus CD49a/ITGA1; and (iv) CD31/PECAM1 versus
CD31/PECAM1). Genes in each cell-specific metagene were selected based on significance (FDR < 0.05,
p-values based on permutations) and high T-values, giving rise to 138 genes highly representative of
each cell population (Supplementary Table S1).
4.2. Patient Datasets
Main cohorts of prostate cancer transcriptome datasets are listed in Supplementary Table S2.
Gene expression data matrices were downloaded from public repositories (Setlur, Taylor, TCGA-PRAD,
Grasso, Kumar, Cai and Best), obtained from authors (Glinsky) or recalculated from raw data (Ehro).
Gene expression data matrices from the individual dataset cohorts were loaded into the ssGSEA
module from the GenePattern software. The output enrichment values were transformed using z-log2
standardization to allow direct comparison of enrichment scores from different dataset cohorts. z-log2
standardization transformed unlogged enrichment scores so that the mean value equals 0 and standard
deviation equals 1. Scaling and centering the data with z-log2 normalization strategy avoids outlier
issues and allows each feature to have equal relevance. In addition, ssGSEA methods do not require
the datasets to have the same expression distribution, since the algorithm computes the enrichment
score based on the gene rank, making the results easily comparable and similarly distributed.
4.3. Metagene Scores Calculation
Single-sample gene set enrichment analysis (ssGSEA) [38] was applied to calculate enrichment
scores of each of the four metagenes in each sample. Each ssGSEA enrichment score represents the
degree to which the genes in a particular metagene are coordinately up or downregulated within a
sample. ssGSEA was computed in the prostate datasets using default settings of the module version
from GenePattern software (Broad Institute). The output of each dataset consists of enrichment values
per sample per metagene. Scores were further transformed into z-log2.
4.4. Patient Stratification for Kaplan-Meier Curves
Patients with coupled gene expression and clinical follow-up data were allocated in 3 groups
depending on Luminal enrichment (LumE) score values: LumElow, quartile q1; LumEintermed, quartiles
q2 and q3; and LumEhigh, quartile q4. Kaplan–Meier curves were obtained using Statistical Package
for the Social Sciences (SPSS) 17.0 (IBM, New York, NY, USA).
4.5. Time Series Analysis
Massie dataset [39] was used to analyze genes regulated by androgen in prostate cancer. Briefly,
LNCaP cells were grown for 72 h in Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented
with 10% charcoal dextran stripped fetal bovine serum (FBS). Samples harvested for transcriptome
analyses comprised: (i) 3 time zero samples; (ii) 10 vehicle (ethanol) control samples taken at 2, 4, 8, 12,
and 24 h in duplicate; (iii) 36 androgen (R1881) treated samples taken every 30 min for 4 h then every
hour until 24 h following treatment (with replicates at 1, 2, 4, 8, 12, 16, 20, and 24 h). Expression data
were downloaded from gene expression omnibus GEO (GSE18684) and metagene scores calculated
using ssGSEA (see above). Significance of correlation between time and changes in metagene score
values was calculated with Fisher’s Kappa statistics using the JMP software (SAS Institute, Cary,
NC, USA).
4.6. Differential Expression between LumElow and Non-LumElow Human Primary Tumors
GSEA was computed between LumElow (quartile q1) and non-LumElow (quartile q2, q3, and q4)
samples using c5.bp genesets from the Molecular Signature Database.
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4.7. Development of LumElow Gene Mini-Classifier
Discriminant function analysis (DFA) is a multivariate technique for describing a mathematical
function that will distinguish among predefined groups of samples. Specifically, we used the classical
discriminant analysis or linear discriminant analysis. TCGA-PRAD dataset was used as training
dataset to derive the DFA-based classification model. Preliminary filtering was performed to remove
genes not detectable in all platforms used in the different datasets. Validation was then performed in
the Setlur, Taylor, and Glinsky datasets. Each sample in the dataset was previously labeled depending
on the LumE score: samples belonging to the first quartile (q1, 25th quartile with lowest values) of the
LumE scores were assigned to the “LumElow” group; samples with LumE scores belonging to quartiles
q2, q3, and q4, were considered “non-LumElow” group. Feature selection was performed on common
genes between all 4 datasets (n = 5812) with fold change >1.25 or <−1.25 between the 2 groups of
samples (n = 3432). Forward stepwise variable selection was used, such that the 10 genes with highest
discriminant performance were selected: AMACR, ANXA3, IDH1, KLK3, SLC13A3, C3, COL4A1,
CYP7A1, MORF4L2, and RRM1. Discriminant coefficients were calculated for these genes, so that
positive or negative coefficient values were associated with genes overexpressed or underexpressed in
non-LumElow samples, respectively. DFA analysis was done using the JMP software (SAS Institute).
4.8. Immunohistochemistry
A tissue microarray (TMA) containing 46 primary prostate tumors was constructed as previously
described [40]. The Independent Ethical Committee of “Policlinico Tor Vergata” approved the study
protocol (Reference number #129.18). All experimental procedures were carried out according to the
Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was
obtained from all patients prior to surgery. Specimens were handled and procedures carried out in
accordance with the approved guidelines. Paraffin-embedded surgical samples were obtained to
perform histological classifications and tissues microarray (TMA) construction. Serial TMA paraffin
sections were used for immunohistochemistry analysis. Staining was performed using anti-Collagen
IV alpha1 (COL4A1) monoclonal antibody (Sigma Aldrich, Milan, Italy SAB4200709). Antigen retrieval
was performed on 4 µm thick paraffin sections using EDTA citrate pH 7.8 buffers for 30 min at 95 ◦C.
Sections were then incubated for 1 h at room temperature with the mouse monoclonal antibody
anti-COL4A1 (clone col-94; 8 µg/mL). Washings were performed with PBS/Tween20 pH 7.6. Reactions
were revealed by HRP-labeled-streptavidin and a biotinylated anti-pan secondary antibody-DAB
Detection Kit (UCS Diagnostic, Rome, Italy). IHC staining was scored independently by two expert
pathologists to establish the degree of staining positivity in each sample.
4.9. Statistical Analysis
Receiver operator characteristic (ROC) curve was calculated using SPSS Statistics 17.0 and
JMP software (SAS Institute, Cary, NC, USA). ROC plots graphically illustrate the performance of
binary classifier system, that is, a parameter that distinguished between two groups of samples,
like normal/tumor or prostate cancer/non-prostate cancer. The area under the curve (AUC) is a measure
of how well the parameter distinguish between the two groups, with AUC values near 1 indicating
good discriminating power of the variable and values near 0 no or limited power. T-test to obtain
metagenes was performed with MultiExperiment Viewer (MeV). Times series analysis and DFA were
done using JMP software (SAS Institute, Cary, NC, USA). GenePattern webserver was used to obtain
ssGSEA scores for custom metagenes, as well as standard GSEA.
4.10. Impact of Drug Treatments in GEMMs and Human Cancer Cell Lines
Transcriptomic data from control and drug-treated prostate cancer GEMMs were retrieved from
Aytes et al. [29] (GSE53202) (Supplementary Table S2). Metagene scores were calculated before and after
treatment using ssGSEA. Drugs inducing an increase of LumE score >2 were listed. Transcriptomic
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data from PC3 and VCaP cells before and after drug treatment with drug compounds were retrieved
from the LINCS database. Increase in LumE score was assessed using CLUE enrichment algorithm
(Cluster Expander of Compound Graphs). Compounds inducing a positive change in LumE score
and/or a negative change in BasE were reported.
5. Conclusions
This study describes an innovative approach based on prostate-specific gene signatures for
discriminating high-risk prostate tumors and identifying alternative therapeutic strategies to improve
treatment efficacy and clinical outcome in prostate cancer patients. Using this approach, we observed
a distinct subgroup of primary tumors that have low luminal features and increased risk of recurrence
under androgen deprivation therapy. We derived a 10-gene classifier that could be applied in clinical
studies to identify low luminal prostate tumors and support clinical management of the patients.
Compounds able to revert the low luminal status provide a novel area of investigation and may
represent a new strategy against aggressive tumors.
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